GlaxoSmithKline Offering Free Access to Potential Malaria Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK CEO Andrew Witty is making another push for cooperation in malaria drug research, offering access to 13,500 compounds and the chance for 60 scientists to work at its research centre in Spain.
You may also be interested in...
Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies
MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development
GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives
Tres Cantos lab's initial focus is on on malaria, tuberculosis, and kinetoplastid diseases.
GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives
Tres Cantos lab's initial focus is on on malaria, tuberculosis, and kinetoplastid diseases.